KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Free Cash Flow: 2016-2024

Historic Free Cash Flow for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $243.2 million.

  • Amneal Pharmaceuticals' Free Cash Flow fell 14.96% to $106.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $264.3 million, marking a year-over-year decrease of 0.71%. This contributed to the annual value of $243.2 million for FY2024, which is 19.57% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Free Cash Flow stood at $243.2 million for FY2024, which was down 19.57% from $302.4 million recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Free Cash Flow high stood at $322.6 million for FY2020, and its period low was $18.7 million during FY2022.
  • Over the past 3 years, Amneal Pharmaceuticals' median Free Cash Flow value was $243.2 million (recorded in 2024), while the average stood at $188.1 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Free Cash Flow crashed by 90.37% in 2022, and later skyrocketed by 1,517.51% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Free Cash Flow (Yearly) stood at $322.6 million in 2020, then tumbled by 39.83% to $194.1 million in 2021, then slumped by 90.37% to $18.7 million in 2022, then soared by 1,517.51% to $302.4 million in 2023, then dropped by 19.57% to $243.2 million in 2024.